Antibody-drug conjugates (ADCs) belong to a new class of compounds conceived as targeted therapy for the treatment of cancer.
A typical ADC consists of three components: a monoclonal antibody chemically bond to a cytotoxic drug by a specific linker.
The antibody selectively targets a tumor cells (usually a protein that, ideally, is only to be found in or on tumor cells) and attaches to its surface. The interaction between the antibody and the antigen (the target protein) generates the absorption and internalization of the antibody together with the cytotoxin within the tumor cell and, subsequently, the cytotoxic drug is released to kills the same cancer cell.
Nowadays different innovative pharmaceutical companies are applying these complex technologies to develop new targeted oncology products with higher safety profile.
Leveraging the synergies of Cerbios Chemical and Biological Divisions and a natural evolution of established competence in the Monoclonal Antibodies (mAbs) and in the Highly Potent Active Ingredient (HPAIs) process development and cGMP manufacturing, Cerbios offers process development and manufacturing services for Antibody Drug Conjugates (ADCs).